IRIS
BELCARO, Giovanni
 Distribuzione geografica
Salva come PNG Salva come JPEG
Continente #
NA - Nord America 6.707
AS - Asia 5.260
EU - Europa 5.105
SA - Sud America 1.158
AF - Africa 83
OC - Oceania 36
Continente sconosciuto - Info sul continente non disponibili 15
AN - Antartide 1
Totale 18.365
Salva come PNG Salva come JPEG
Nazione #
US - Stati Uniti d'America 6.567
SG - Singapore 1.968
CN - Cina 1.542
BR - Brasile 935
UA - Ucraina 930
IE - Irlanda 899
IT - Italia 681
TR - Turchia 675
SE - Svezia 574
GB - Regno Unito 509
VN - Vietnam 437
FR - Francia 414
DE - Germania 385
IN - India 217
FI - Finlandia 201
RU - Federazione Russa 160
AR - Argentina 110
PL - Polonia 106
HK - Hong Kong 89
ID - Indonesia 65
CA - Canada 56
MX - Messico 55
ES - Italia 43
EC - Ecuador 42
BD - Bangladesh 39
JP - Giappone 36
BE - Belgio 35
KR - Corea 35
ZA - Sudafrica 32
AU - Australia 29
NL - Olanda 29
AT - Austria 27
TH - Thailandia 27
CZ - Repubblica Ceca 24
IR - Iran 22
PY - Paraguay 19
IQ - Iraq 18
CO - Colombia 17
PK - Pakistan 17
PT - Portogallo 14
EG - Egitto 13
EU - Europa 13
TW - Taiwan 13
CH - Svizzera 12
TN - Tunisia 12
VE - Venezuela 12
GR - Grecia 10
CL - Cile 9
LT - Lituania 9
MA - Marocco 9
PE - Perù 8
SK - Slovacchia (Repubblica Slovacca) 8
UZ - Uzbekistan 8
NZ - Nuova Zelanda 7
RO - Romania 7
IL - Israele 6
JM - Giamaica 6
JO - Giordania 6
NI - Nicaragua 6
AE - Emirati Arabi Uniti 5
DK - Danimarca 5
DZ - Algeria 5
HR - Croazia 5
PH - Filippine 5
SA - Arabia Saudita 5
DO - Repubblica Dominicana 4
KE - Kenya 4
KZ - Kazakistan 4
NP - Nepal 4
SV - El Salvador 4
AL - Albania 3
BG - Bulgaria 3
BO - Bolivia 3
KW - Kuwait 3
MY - Malesia 3
OM - Oman 3
UY - Uruguay 3
CR - Costa Rica 2
GT - Guatemala 2
LU - Lussemburgo 2
PS - Palestinian Territory 2
SC - Seychelles 2
SI - Slovenia 2
TT - Trinidad e Tobago 2
XK - ???statistics.table.value.countryCode.XK??? 2
AQ - Antartide 1
AZ - Azerbaigian 1
BA - Bosnia-Erzegovina 1
BB - Barbados 1
BN - Brunei Darussalam 1
BY - Bielorussia 1
CG - Congo 1
CI - Costa d'Avorio 1
DM - Dominica 1
ET - Etiopia 1
GA - Gabon 1
GE - Georgia 1
HU - Ungheria 1
KG - Kirghizistan 1
LK - Sri Lanka 1
Totale 18.356
Salva come PNG Salva come JPEG
Città #
Singapore 1.422
Jacksonville 1.180
Chandler 906
Dublin 892
Princeton 438
Dallas 372
Izmir 363
Nanjing 349
Southend 346
Beijing 307
Ashburn 290
Wilmington 190
Cambridge 188
Altamura 183
Ho Chi Minh City 170
Santa Clara 166
Los Angeles 151
Ann Arbor 129
Tongling 129
Nanchang 120
Dearborn 110
The Dalles 99
Hanoi 96
Hong Kong 76
New York 76
São Paulo 73
Boardman 71
Buffalo 68
Redondo Beach 66
Kraków 65
Shenyang 63
Hebei 56
Kunming 48
Tianjin 48
Woodbridge 44
Jiaxing 41
Munich 41
Catania 32
Warsaw 32
Changsha 31
London 30
Norwalk 30
Brussels 29
Rio de Janeiro 29
Da Nang 28
Tokyo 28
Milan 26
Washington 25
Seattle 23
Chieti 22
Hangzhou 22
Falls Church 21
Ankara 20
Curitiba 20
Denver 20
Houston 20
Orem 20
Brooklyn 19
Chicago 19
Frankfurt am Main 19
Guangzhou 19
Rome 19
Hefei 18
Moscow 18
Vienna 18
Atlanta 17
Chennai 17
Brno 16
Grevenbroich 16
Haiphong 16
Lanzhou 16
Sydney 16
Belo Horizonte 15
Istanbul 15
Johannesburg 15
San Mateo 15
Guayaquil 14
Helsinki 14
Jinan 14
Montreal 14
Mumbai 14
Shanghai 14
Biên Hòa 13
Boston 13
Foggia 13
Manchester 13
Changchun 12
Mexico City 12
Ningbo 12
Quito 12
Toronto 12
Amsterdam 11
Augusta 11
Bengaluru 11
Hanover 11
Salvador 11
Turku 11
Auburn Hills 10
Bangkok 10
Dhaka 10
Totale 10.555
Salva come PNG Salva come JPEG
Nome #
Supplementary prevention and management of asthma with quercetin phytosome: a pilot registry 398
Beanblock® (standardized dry extract of Phaseolus vulgaris) in mildly overweight subjects: a pilot study. 177
Robuvit® (Quercus robur extract) supplementation in subjects with chronic fatigue syndrome and increased oxidative stress. A pilot registry study 147
Aescin and microcirculatory activity. Effects of accessory components on clinical and microcirculatory efficacy. 144
Venoruton vs Daflon: evaluation of effects on qualità of life chronic venous insuffciency 144
Centella asiatica (Centellicum®) facilitates the regular healing of surgical scars in subjects at high risk of keloids. 143
A short-term vs a long-term infusion plan. A 20-week, European randomized trial. Analysis of efficacy and costs. 142
Robuvit® and endurance in triathlon: improvements in training performance, recovery and oxidative stress 140
Long-haul flights, edema, and thrombotic events: prevention with stockings and Pycnogenol® supplementation (LONFLIT Registry Study). 137
Postoperative pulmonary infections: role of antibiotic treatment 136
The lung in systemic vasculitis: Radiological patterns and differential diagnosis 135
Incidence of perioperative stroke during peripheral revascularization or aortocoronary bypass in patients with carotid bruit and stenosis 131
Topical heparin: New observations 131
Pressure and microcirculatory effects of treatment with lercanidipine in hypertensive patients and in vascular patients with hypertension 125
An open, supplement, registry study Arborvitae (R) for prevention of arthrosis-related pain during exercise 125
Treatment of ankle sprain in patients with vascular diseases of the lower limbs 124
Treatment of Osteoarthritis with Pycnogenol®. The SVOS (San Valentino Osteo-arthrosis Study). Evaluation of Signs, Symptoms,Physical Performance and Vascular Aspects 122
Management of Varicose Veins and Chronic Venous Insufficiency in a Comparative Registry with Nine Venoactive Products in Comparison with Stockings 120
Improvement in mood, oxidative stress, fatigue, and insomnia following supplementary management with Robuvit® 119
Mononucleosis-related fatigue: supplementary management with Robuvit®. 119
Jet-lag: prevention with Pycnogenol. Preliminary report: evaluation in healthy individuals and in hypertensive patients 118
Effects of pycnogenol on endothelial dysfunction in borderline hypertensive, hyperlipidemic, and hyperglycemic individuals: the borderline study. 118
[European trial of PGE1 alpha cyclodextrin. Short-term vs. long-term therapy in intermittent claudication] 117
[Breast cancer. Epidemiology and other factors related to incidence in various populations]. 117
Comparison of Pycnogenol and Daflon in treating chronic venous insufficiency: a prospective, controlled study 117
Total triterpenic fraction of Centella asiatica in chronic venous insufficiency and in high-perfusion microangiopathy. 116
TECA (Titrated Extract of Centella Asiatica): new microcirculatory, biomolecular, and vascular application in preventive and clinical medicine. A status paper. 115
Management of functional, hepatic damage after chemotherapy with Liverubin (pharma-standard silymarin). 115
Prevention of edema and flight microangiopathy with Venoruton (HR), (0-[beta-hydroxyethyl]-rutosides) in patients with varicose veins 114
Bilberry extracts are not created equal: the role of non anthocyanin fraction. Discovering the "dark side of the force" in a preliminary study 114
Temporary kidney dysfunction: Robuvit® supplementation in initial, transient kidney insufficiency and micro-macro albuminuria 113
Aescin: microcirculatory activity. Effects of accessory components on clinical and microcirculatory efficacy. 112
Clinical improvement in chronic venous insufficiency signs and symptoms with Venoruton® (HR): an 8-month, open-registry, cost-efficacy study. 111
Pycnogenol® supplementation improves the control of irritable bowel syndrome symptoms. 111
Thyroid cysts treatment with the sclerosing agent Atossiclerol. Long-term (5 to 15 years) follow-up. 110
Superficial vein thrombosis (SVT), diffusion of thrombotic diseases, and increased global thrombogenicity: SVT as an important spy disease indicating environmental contamination by estrogens - Introduction 110
Evaluation of treatment of diabetic microangiopathy with total triterpenic fraction of Centella Asiatica: a clinical prospective randomized trial with a microcirculatory model. 109
Circulating endothelail cells in venous blood as a marker of endothelial damage in chronic venous insufficiency: improvement with venoruton 109
Clinical evaluation of defibrotide in the treatment of arterial and venous vascular disease. A preliminary report. 109
PGE(1) treatment of severe intermittent claudication (short-term versus long-term, associated with exercise)--efficacy and costs in a 20-week, randomized trial 108
Diabetic ulcers: microcirculatory improvement and faster healing with pycnogenol. 107
Variations in C-reactive protein, plasma free radicals and fibrinogen values in patients with osteoarthritis treated with Pycnogenol. 107
Total triterpenic fraction of Centella asiatica in the treatment of venous hypertension: a clinical, prospective, randomized trial using a combined microcirculatory model. 106
Management of superficial vein thrombosis and thrombophlebitis: status and expert opinion document. 106
5-Year Control and Treatment of Edema and Increased Capillary Filtration in Venous Hypertension and Diabetic Microangiopathy Using O-(β-Hydroxyethyl)-Rutosides: A Prospective Comparative Clinical Registry 106
A natural pharma standard supplement formulation to control treatment-related toxicity and oxidative stress in genitourinary cancer: a preliminary study 106
Behçet syndrome: effects of Pycnogenol® supplementation during regression phases. 106
Activity of some physiological modulators in reducing the side effects of levothyroxine in patients suffering from primary hypothyroidism. 105
Management of uncomplicated ankle sprains with topical or oral ketoprofen treatment. A registry study 105
Effectiveness of a novel boswellic acids delivery form (Casperome®) in the management of grade II ankle sprains due to sport trauma - a registry study 105
Supplementary management with Pycnogenol® in Parkinson's disease to prevent cognitive impairment. 105
The value of segmental pressure measurement in the assessment of peripheral vascular disease. 104
[Comparison of netilmicin with other aminoglycosides in severe surgical infections]. 104
Venous and diabetic ulcerations: management with topical multivalent silver oxide ointment. 104
Microcirculatory effects of Viatromb® spray gel heparin in chronic venous insufficiency: Evaluation of TcPO2 and PCO2 - A product evaluation study 104
Supplementation with a lecithin-based delivery form of Boswellia serrata extract (Casperome®) controls symptoms of mild irritable bowel syndrome 102
Capillary filtration in venous hypertension: evaluation with the vacuum suction chamber device and strain-gauge plethysmography. 101
Recurrence of retinal vein thrombosis with Pycnogenol® or Aspirin® supplementation: a registry study 101
Improvement of common cold with Pycnogenol®: a Winter registry study. 100
Pycnogenolà supplementation improves health risk factors in subjects with metabolic syndrome 100
A controlled study shows daily intake of 50 mg of French Pine Bark Extract (Pycnogenol®) lowers plasma reactive oxygen metabolites in healthy smokers. 100
Improvement in signs and symptoms in psoriasis patients with Pycnogenol® supplementation. 99
Prevention of recurrent venous thrombosis and post-thrombotic syndrome. 99
Robuvit®: improvement of fatigue in medical convalescence. 99
Venous ulcers: microcirculatory improvement and faster healing with local use of Pycnogenol 98
Local heparin, superficial vein thrombosis 98
Artificial Saliva in Diabetic Xerostomia (ASDIX): Double Blind Trial of Aldiamed® Versus Placebo 98
Nomograms used to define the short-term treatment with PGE(1) in patients with intermittent claudication and critical ischemia. The ORACL.E (Occlusion Revascularization in the Atherosclerotic Critical Limb) Study Group. The European Study. 97
Interaction study between antiplatelet agents, anticoagulants, diabetic therapy and a novel delivery form of quercetin. 97
Treatment of Diabetic Microangiopathy and Edema with Total Triterpenic Fraction of Centella Asiatica: A Prospective, Placebo-Controlled Randomized Study. 95
Pycnogenol may alleviate adverse effects in oncologic treatment 94
Mirtogenol® supplementation in association with dorzolamide-timolol or latanoprost improves the retinal microcirculation in asymptomatic patients with increased ocular pressure 94
Venoruton®: post thrombotic syndrome. Clinical improvement in venous insufficiency (signs and symptoms) with Venoruton®. A five-year, open-registry, efficacy study. 93
Supplementary management of functional, hepatic damage with Liverubin (pharma-standard Silymarin). A 3-month registry. 93
Increase in Echogenicity of Echolucent Carotid Plaques After Treatment with Total Triterpenic Fraction of Centella Asiatica: A Prospective, Placebo-Controlled, Randomized Trial. 92
O-(beta-hydroxyethyl)-rutosides systemic and local treatment in chronic venous disease and microangiopathy: an independent prospective comparative study 92
Cramps and Muscular Pain: Prevention with Pycnogenol((R)) in Normal Subjects, Venous Patients, Athletes, Claudicants and in Diabetic Microangiopathy 92
[Reduction of cardiovascular morbidity/mortality in arteriopathies treated ith PGE1 alpha-cyclodextrin] 92
Pycnogenol®+Centellicum®, post-stent evaluation: prevention of neointima and plaque re-growth 92
Treatment of edema and increased capillary filtration in venous hypertension with total triterpenic fraction of Centella asiatica: a clinical, prospective, placebo-controlled, randomized, dose-ranging trial. 91
Activity of some physiological modulators in reducing the side effects of levothyroxine in patients suffering from primary hypothyroidism. 91
Microcirculatory Effects of Total Triterpenic Fraction of Cenetlla asiatica in Chronic Venous Hypertension: Measurement by Laser Doppler, TcPo2-CO2, and Leg Volumetry 90
Oxidative stress following administration of levothyroxine in subjects suffering from primary hypothyroidism. 90
The COFU3 Study. Improvement in cognitive function, attention, mental performance with Pycnogenol® in healthy subjects (55-70) with high oxidative stress 90
Carotid and femoral ultrasound morphology screening and cardiovascular events in low risk subjects: a 10 year follow-up study (the CAFES-CAVE Study). 89
Assessment of the activity of an oral contraceptive on the levels of oxidative stress and changes in oxidative stress after co-treatment with two different types of physiological modulators with antioxidant action. 89
Oxygen-free radical decrease in hypertensive patients treated with lercanidipine 88
Supplementation with Pycnogenol® improves signs and symptoms of menopausal transition. 88
Lady Prelox® improves sexual function in generally healthy women of reproductive age. 88
Managing ulcerative colitis in remission phase: usefulness of Casperome®, an innovative lecithin-based delivery system of Boswellia serrata extract 88
Interaction study between antiplatelet agents, anticoagulants, thyroid replacement therapy and a bioavailable formulation of curcumin (Meriva®). 88
Prevention of diffuse, minimal lymphatic "retention" with Robuvit®: a concept, supplement registry study 88
Treatment of long-distance intermittent claudication with pentoxifylline: a 12-month, randomized trial. 87
Valutazione dei fattori di rischio per lo stroke in pazienti con insufficienza cerebrovascolare 87
Topical formulation of heparin is effective in reducing the symptoms of superficial venous thrombosis: a monocenter, observer-blind, placebo-controlled randomized study. 87
PycnoRacer®, a fitness drink including Pycnogenol®, improves recovery and training in the Cooper test 87
HR (Paroven, Venoruton; 0-(beta-hydroxyethyl)-rutosides) in venous hypertensive microangiopathy: a prospective, placebo-controlled, randomized trial. 86
Improvement of diabetic microangiopathy with pycnogenol: A prospective, controlled study. 85
Prevention of edema in long flights with Pycnogenol 85
Computerized ultrasonic angiography. Current applications and comparison with other noninvasive and invasive methods 85
Totale 10.967
Salva come PNG Salva come JPEG
Categoria #
all - tutte 76.003
article - articoli 0
book - libri 0
conference - conferenze 0
curatela - curatele 0
other - altro 0
patent - brevetti 0
selected - selezionate 0
volume - volumi 0
Totale 76.003
Salva come PNG Salva come JPEG


Totale Lug Ago Sett Ott Nov Dic Gen Feb Mar Apr Mag Giu
2020/2021521 0 0 0 0 0 262 20 9 84 92 19 35
2021/2022870 16 18 15 166 77 25 19 65 68 17 101 283
2022/20232.720 272 406 156 284 234 570 180 176 276 26 88 52
2023/20241.146 88 50 65 26 48 287 334 38 24 50 33 103
2024/20253.392 264 688 530 55 78 93 64 149 394 147 281 649
2025/20263.886 486 302 956 1.378 544 220 0 0 0 0 0 0
Totale 18.848